Needham downgrades Biogen to Hold on lack of share catalysts
Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...
The Pharma Letter19m
Opuviz is latest EC-approved ophthalmology biosimilar
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...